Harmony Biosciences (HRMY) Stock Price & Analysis
Score
AI Analysis
SnapshotHarmony Biosciences Holdings mixes growth with a still-reasonable multiple — Growth 76/100 with P/E 11.2, about 25% below its own multi-year median. Under the hood: P/E 11.2, about 25% below its own multi-year median, plus revenue compounding ~26% annually over recent years. Street targets still imply ~44% upside.
Price History
Price: —
Fair value: —
—
P/E (TTM): —
Net Income (TTM): —
Score: —
—
Score Breakdown
Market percentile scores loading…
Value
Growth
Quality
Financial Summary
Harmony Biosciences Holdings, Inc. (HRMY) last printed $33.76. Equity value is $1.98B. Trailing earnings multiple 11.04. The revenue row is reported history. Targets and ratings are on the forecast page.
Financials
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| $0.00 | $6M | $159.74M | $305.44M | $437.86M | $582.02M | $714.73M | $868.45M |
About
Harmony Biosciences Holdings, Inc. is a commercial-stage pharmaceutical firm dedicated to developing and marketing therapies for individuals in the United States who suffer from rare neurological conditions. Their flagship product, WAKIX, is a prescription medication designed to treat excessive daytime sleepiness in adult patients diagnosed with narcolepsy. The company, which was founded in 2017, was formerly known as Harmony Biosciences II, Inc. before adopting its current name in February 2020. Harmony Biosciences Holdings, Inc. operates out of Plymouth Meeting, Pennsylvania.